NCT06224907进行中（未招募）3 期
GENEr8-JPN: A Phase 3 Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of BMN 270, an Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Japanese Hemophilia A Patients With Residual FVIII Levels ≤ 1 IU/dL Receiving Prophylactic FVIII Infusions
适应症
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 入组人数
- 6
- 试验地点
- 8
- 主要终点
- Change in the human coagulation factor VIII (hFVIII) activity, as measured by chromogenic substrate assay, during Weeks 49 to 52 post BMN 270 infusion from Baseline.
研究概览
简要总结
This Phase III clinical study will evaluate the safety and effectiveness of valoctocogene roxaparvovec in Japanese patients with severe hemophilia A.
详细描述
This is a Phase 3, single-arm, open-label study in Japanese hemophilia A (HA) participants with endogenous coagulation factor VIII (FVIII) activity levels <1 IU/dL treated continuously with prophylactic exogenous FVIII for a minimum of 1 year prior to enrollment. Participants will be enrolled at approximately 10 sites in Japan. Participants must have high-quality, well-documented historical data available concerning previous bleeding episodes and exogenous FVIII usage over the previous 12 months in order to be eligible to enroll in the study. Approximately 6 Japanese adult participants with severe HA will receive a 6E13 vg/kg dose of BMN 270 as a single intravenous infusion.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Japanese males ≥18 years of age with HA and endogenous FVIII activity levels <1 IU/dL as evidenced by medical history, at the time of signing the informed consent
- •Must have been on prophylactic FVIII replacement therapy for at least 12 months prior to study entry. High-quality, well-documented historical data concerning bleeding episodes and FVIII usage over the previous 12 months must be available.
- •Treated/exposed to FVIII concentrates for a minimum of 150 exposure days.
- •Willing and able to provide written, signed informed consent after the nature of the study has been explained and prior to any study-related procedures.
- •No previous documented history of a detectable FVIII inhibitor, and results from a Bethesda assay or Bethesda assay with Nijmegen modification of less than 0.6 Bethesda Units (BU) or less than 1.0 BU for laboratories with a historical lower sensitivity cutoff for inhibitor detection of 1.0 BU on 2 consecutive occasions at least 1 week apart within the past 12 months (at least 1 of which should be tested at the central laboratory).
- •Sexually active participants must agree to use an acceptable method of effective contraception
- •Willing to abstain from alcohol consumption for at least the first 52 weeks following BMN 270 infusion.
排除标准
- •Detectable pre-existing antibodies to the AAV5 capsid.
- •Any evidence of active infection or any immunosuppressive disorder, except for human immunodeficiency virus (HIV) infection. HIV-positive participants who meet all other eligibility criteria may be included.
- •Significant liver dysfunction
- •Most recent, prior FibroScan or liver biopsy showing significant fibrosis
- •Evidence of any bleeding disorder not related to HA.
- •Platelet count of <100E9/L.
- •Creatinine ≥1.5 mg/dL.
- •Liver cirrhosis of any etiology as assessed by liver ultrasound.
- •Chronic or active hepatitis B
- •Active hepatitis C
- •Active malignancy, except non-melanoma skin cancer
- •History of hepatic malignancy
- •History of arterial or venous thromboembolic events
- •Known inherited or acquired thrombophilia, including conditions associated with increased thromboembolic risk, such as atrial fibrillation
- •Treatment with any investigational product (IP) within 30 days or 5 half-lives of the IP prior to the Screening period.
- •Any condition that, in the opinion of the investigator or sponsor would prevent the participant from fully complying with the requirements of the study
- •Prior treatment with any vector or gene transfer agent.
- •Major surgery planned in the 52-week period following the infusion with BMN
- •Use of systemic immunosuppressive agents, not including corticosteroids, or live vaccines within 30 days before the BMN 270 infusion.
- •Concurrent enrollment in another clinical study unless it is an observational (non-interventional) clinical study that does not interfere with the requirements of the current protocol or have the potential to impact the evaluation of efficacy and safety of BMN 270 and with prior consultation with the medical monitor.
- •Known allergy or hypersensitivity to BMN 270 IP formulation.
- •Unwilling to receive blood or blood products for treatment of an AE and/or a bleeding episode.
结局指标
主要结局
Change in the human coagulation factor VIII (hFVIII) activity, as measured by chromogenic substrate assay, during Weeks 49 to 52 post BMN 270 infusion from Baseline.
时间窗: 52 Weeks
The change from baseline in FVIII activity, as measured by chromogenic substrate assay, during Weeks 49 to 52 post-BMN 270 infusion. Each subject's FVIII activity level during Week 49 to 52 is defined as the median of the values obtained during week 49-52 with the analysis window defined. Baseline: prior to BMN 270 infusion while receiving FVIII prophylaxis. The baseline value is imputed as 1 IU/dL for each subject.
次要结局
- Change from Baseline in Hemophilia-Specific Health-Related Quality of Life Questionnaire for Adults (Haemo-QoL-A) total score, physical functioning, role functioning, and consequences of bleeding domain scores at Week 52 of study post-BMN 270 infusion(Baseline to Week 52)
- Change in the annualized utilization (IU/kg/year) of exogenous FVIII replacement therapy in the efficacy evaluation period (EEP) ("Post FVIII Prophylaxis to Last Visit") from the Baseline utilization of exogenous FVIII replacement therapy.(Baseline to at least Week 52)
- Change in the annualized bleeding rate (i.e., number of bleeding episodes per year) requiring exogenous FVIII replacement treatment therapy in the efficacy evaluation period ("Post FVIII Prophylaxis to Last Visit") from Baseline.(Baseline to at least Week 52)
- Change from Baseline in the Haemo-QoL-A worry, emotional impact, and treatment concern domain scores at Week 52 of the study post-BMN 270 infusion.(Baseline to Week 52)
研究者
研究点 (8)
Loading locations...
相似试验
已完成
3 期
Study to Evaluate the Efficacy and Safety of Valoctocogene Roxaparvovec, With Prophylactic Steroids in Hemophilia AHemophilia ANCT04323098BioMarin Pharmaceutical22
已完成
3 期
Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants in MexicoVaccines, PneumococcalNCT00708682Wyeth is now a wholly owned subsidiary of Pfizer225
招募中
3 期
Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA TherapyGEP-NETGastroenteropancreatic Neuroendocrine TumorGastroenteropancreatic Neuroendocrine Tumor DiseaseNeuroendocrine TumorsCarcinoid TumorPancreatic NETCarcinoidNCT05477576RayzeBio, Inc.288
已完成
3 期
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)Von Willebrand DiseaseNCT02932618Baxalta now part of Shire47
已完成
3 期
Study of Biostate® in Children With Von Willebrand DiseaseVon Willebrand DiseaseNCT01213446CSL Behring17